[{"address1": "2000 Sierra Point Parkway", "address2": "Suite 1200", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "650 770 0077", "website": "https://veratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.", "fullTimeEmployees": 152, "companyOfficers": [{"maxAge": 1, "name": "Dr. Marshall W. Fordyce M.D.", "age": 50, "title": "Founder, President, CEO & Director", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 1025450, "exercisedValue": 0, "unexercisedValue": 39235948}, {"maxAge": 1, "name": "Mr. Jason S. Carter", "age": 48, "title": "Chief Legal Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 256700, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert M. Brenner M.D.", "age": 56, "title": "Chief Medical Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 828753, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean P. Grant M.B.A.", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1985, "fiscalYear": 2024, "totalPay": 642000, "exercisedValue": 0, "unexercisedValue": 368374}, {"maxAge": 1, "name": "Mr. David L. Johnson M.B.A.", "age": 54, "title": "Chief Opearating Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joseph R. Young M.B.A.", "age": 51, "title": "Senior VP of Finance & Chief Accounting Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Allen  Ebens B.Sc., Ph.D.", "title": "Executive Vice President of Research", "fiscalYear": 2024, "totalPay": 397024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. S. Sandra Park J.D.", "title": "Senior VP of Legal, Healthcare,Commercial Law, Compliance & Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Debra  Charlesworth", "title": "Vice President of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emma  Haywood", "title": "Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 22.52, "open": 22.08, "dayLow": 21.8, "dayHigh": 22.98, "regularMarketPreviousClose": 22.52, "regularMarketOpen": 22.08, "regularMarketDayLow": 21.8, "regularMarketDayHigh": 22.98, "payoutRatio": 0.0, "beta": 1.128, "forwardPE": -7.3118973, "volume": 1273020, "regularMarketVolume": 1273020, "averageVolume": 1667496, "averageVolume10days": 4533420, "averageDailyVolume10Day": 4533420, "bid": 16.51, "ask": 28.1, "bidSize": 2, "askSize": 2, "marketCap": 1450225280, "fiftyTwoWeekLow": 18.53, "fiftyTwoWeekHigh": 51.61, "fiftyDayAverage": 22.5337, "twoHundredDayAverage": 34.481274, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 900825024, "profitMargins": 0.0, "floatShares": 50492552, "sharesOutstanding": 63774200, "sharesShort": 8947513, "sharesShortPriorMonth": 5958240, "sharesShortPreviousMonthDate": 1745971200, "dateShortInterest": 1748563200, "sharesPercentSharesOut": 0.14029999, "heldPercentInsiders": 0.05155, "heldPercentInstitutions": 1.12409, "shortRatio": 6.75, "shortPercentOfFloat": 0.1617, "impliedSharesOutstanding": 63774200, "bookValue": 8.389, "priceToBook": 2.7106926, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -175459008, "trailingEps": -3.0, "forwardEps": -3.11, "enterpriseToEbitda": -4.666, "52WeekChange": -0.36338186, "SandP52WeekChange": 0.09203708, "quoteType": "EQUITY", "currentPrice": 22.74, "targetHighPrice": 100.0, "targetLowPrice": 23.0, "targetMeanPrice": 64.0, "targetMedianPrice": 65.0, "recommendationMean": 1.42857, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 14, "totalCash": 589833984, "totalCashPerShare": 9.249, "ebitda": -193072992, "totalDebt": 54465000, "quickRatio": 27.104, "currentRatio": 27.682, "debtToEquity": 10.18, "returnOnAssets": -0.23464, "returnOnEquity": -0.39494, "freeCashflow": -97136496, "operatingCashflow": -155255008, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VERA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Vera Therapeutics, Inc.", "longName": "Vera Therapeutics, Inc.", "exchange": "NGM", "messageBoardId": "finmb_683328925", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1749858372, "regularMarketTime": 1749844800, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1620999000000, "postMarketChangePercent": -1.05541, "postMarketPrice": 22.5, "postMarketChange": -0.24, "regularMarketChange": 0.219999, "regularMarketDayRange": "21.8 - 22.98", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1667496, "fiftyTwoWeekLowChange": 4.209999, "fiftyTwoWeekLowChangePercent": 0.22719908, "fiftyTwoWeekRange": "18.53 - 51.61", "fiftyTwoWeekHighChange": -28.87, "fiftyTwoWeekHighChangePercent": -0.55938774, "fiftyTwoWeekChangePercent": -36.33819, "earningsTimestamp": 1746532800, "earningsTimestampStart": 1754483400, "earningsTimestampEnd": 1754915400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.0, "epsForward": -3.11, "epsCurrentYear": -3.30098, "priceEpsCurrentYear": -6.888863, "fiftyDayAverageChange": 0.20629883, "fiftyDayAverageChangePercent": 0.009155124, "twoHundredDayAverageChange": -11.741274, "twoHundredDayAverageChangePercent": -0.34051162, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-05-14", "averageAnalystRating": "1.4 - Strong Buy", "regularMarketChangePercent": 0.976906, "regularMarketPrice": 22.74, "displayName": "Vera Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-06-14"}]